The advent of anti-PDL-1 antibodies in the treatment of advanced gastric carcinomas: A systematic review
| Autor: | Mounica Vorla, Usman Ali Akbar, Aqsa Ashraf, Mounika Pusa, Saman Barham, Adil Khan, Daniya Sheikh, Ammar Yaser Dab, Shaheryar Qazi, Zeeshan Chaughtai, Faiz Anwer |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 40:e16020-e16020 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2022.40.16_suppl.e16020 |
| Popis: | e16020 Background: The poor prognosis of systemic chemotherapy in advanced gastric adenocarcinoma (GC) and gastroesophageal (GE) carcinoma prompted the development of novel agents such as anti-PDL-1 antibodies, which have the potential to overcome drug resistance due to signaling pathway overlap. We study here the safety and efficacy of standalone and combination chemo-immunotherapy in the treatment of advanced GC & GE Carcinomas. Methods: Following the PRISMA guidelines, we searched the literature on PubMed, Cochrane, Embase & clinicaltrials.gov. A total of 300 articles were screened, and 7 studies were included. Results: With anti-PDL-1 inhibitors in phase III clinical trial, the overall survival (OS) was more remarkable in Chemotherapy (CTX) vs. Avelumab (AVE) (5 vs 4.6 mo). However, Nivolumab (NIVO 1mg and NIVO 3mg) significantly prolonged the OS when combined with Ipilimumab (IPI), but the grade > 3 adverse events were reported more in NIVO1 and NIVO3 regimen. Similarly, Pembrolizumab (P) increased both OS and progression-free survival (PFS) when used alone and as combination therapy compared to chemotherapy alone, as illustrated in the table. Conclusions: The anti-PDL-1 inhibitors show promising data to treat advanced or relapsed GC or GE Carcinomas with favorable side effect profiles. However, there is further need for high-quality large prospective randomized clinical trials.[Table: see text] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|